A double-blind placebo-controlled cross-over study with lidoflazine (Clinium) in post-infarction patients.
The effects of lidoflazine on exercise tolerance have been tested during a double-blind cross-over trial in 14 male post-infarction patients with a median age of 47 years (range 24-85). Each treatment phase lasted three months. Lidoflazine dosage was one 60 mg tablet t.i.d. At rest, significant decreases in diastolic blood pressure (DBP) and heart rate (HR) were noted during lidoflazine treatment. Bicycle ergometric tests revealed a significant increase in maximum work load and a significant decrease in the product HRXsystolic BP at a 100 W work load during lidoflazine. No similar changes were recorded during placebo periods. Five patients were able to resume their professional activities whilst on lidofalzine, against only two on placebo.
D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D002986:Clinical Trials as Topic; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008013:Lidoflazine / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy*; D005082:Physical Exertion; D010879:Piperazines / Q000627:therapeutic use*; D010919:Placebos
D010879:Piperazines; D010919:Placebos; D008013:Lidoflazine